Inventurus Knowledge Solutions Ltd
Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
- Market Cap ₹ 33,012 Cr.
- Current Price ₹ 1,924
- High / Low ₹ 2,190 / 1,820
- Stock P/E 89.1
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 30.0 %
- ROE 37.3 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 41.6%
Cons
- Promoter holding has decreased over last quarter: -6.01%
- Debtor days have increased from 58.4 to 72.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: IT - Software Industry: Computers - Software - Medium / Small
Part of BSE IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
| Sep 2023 | Sep 2024 | |
|---|---|---|
| 631 | 1,283 | |
| 399 | 924 | |
| Operating Profit | 232 | 359 |
| OPM % | 37% | 28% |
| 19 | 12 | |
| Interest | 2 | 48 |
| Depreciation | 12 | 57 |
| Profit before tax | 237 | 266 |
| Tax % | 13% | 22% |
| 205 | 209 | |
| EPS in Rs | 12.02 | 12.16 |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 529 | 553 | 764 | 1,031 | 1,818 | |
| 367 | 348 | 466 | 639 | 1,297 | |
| Operating Profit | 162 | 205 | 298 | 392 | 521 |
| OPM % | 31% | 37% | 39% | 38% | 29% |
| 31 | 16 | 1 | -2 | 40 | |
| Interest | 7 | 8 | 7 | 6 | 61 |
| Depreciation | 40 | 30 | 23 | 25 | 59 |
| Profit before tax | 145 | 183 | 269 | 359 | 442 |
| Tax % | 5% | 9% | 13% | 15% | 16% |
| 137 | 165 | 233 | 305 | 370 | |
| EPS in Rs | 166.73 | 200.10 | 13.61 | 17.86 | 21.68 |
| Dividend Payout % | 0% | 12% | 393% | 0% | 46% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 76% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 42% |
| Last Year: | 37% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 17 | 17 | 17 | 17 |
| Reserves | 275 | 449 | 630 | 812 | 1,141 | 1,360 |
| 0 | 76 | 65 | 52 | 1,311 | 935 | |
| 151 | 53 | 75 | 107 | 411 | 479 | |
| Total Liabilities | 434 | 586 | 788 | 988 | 2,880 | 2,791 |
| 36 | 87 | 76 | 59 | 1,833 | 1,803 | |
| CWIP | 0 | 0 | 0 | 0 | 3 | 1 |
| Investments | 1 | 14 | 16 | 32 | 195 | 44 |
| 397 | 485 | 695 | 898 | 849 | 943 | |
| Total Assets | 434 | 586 | 788 | 988 | 2,880 | 2,791 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 163 | 175 | 233 | 288 | 210 | |
| -79 | -167 | -82 | -158 | -1,137 | |
| -41 | -37 | -59 | -152 | 780 | |
| Net Cash Flow | 43 | -28 | 92 | -22 | -147 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 51 | 49 | 46 | 57 | 73 |
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | 51 | 49 | 46 | 57 | 73 |
| Working Capital Days | 20 | 48 | 21 | 26 | 6 |
| ROCE % | 47% | 47% | 50% | 30% |
Documents
Announcements
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Order From Reserve Bank Of India, Central Office, Mumbai.
6h - RBI compounding order on past share allotment contraventions.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR), Regulations, 2015 ('Listing Regulations')
16 Jan - Board meeting to approve Q4 financial results.
-
Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations, 2018 For The Quarter Ended December 31, 2024.
14 Jan - Certificate under Regulation 74(5) for Q4 2024.
-
Intimation Of Change In Name Of Registrar And Share Transfer Agent Of The Company.
2 Jan - Change of Registrar and Share Transfer Agent name.
- Closure of Trading Window 27 Dec
Business Overview:[1]
IKSL is a technology-enabled healthcare solutions provider which offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. It partners with an outpatient and inpatient health care organizations, enabling them to deliver superior clinical care through a **fee for value model **